Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) insider Pamela J. Cramer sold 4,099 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $50.03, for a total transaction of $205,072.97. Following the transaction, the insider now directly owns 13,500 shares in the company, valued at approximately $675,405. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Rhythm Pharmaceuticals Price Performance
RYTM traded up $0.22 during trading on Wednesday, hitting $49.31. 420,459 shares of the stock traded hands, compared to its average volume of 555,087. The firm has a 50-day moving average of $46.97 and a 200 day moving average of $42.73. Rhythm Pharmaceuticals, Inc. has a 12-month low of $20.97 and a 12-month high of $53.92. The firm has a market capitalization of $3.01 billion, a P/E ratio of -10.60 and a beta of 2.07.
Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) last posted its earnings results on Tuesday, August 6th. The company reported ($0.55) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.16. Rhythm Pharmaceuticals had a negative net margin of 254.88% and a negative return on equity of 221.65%. The company had revenue of $29.08 million during the quarter, compared to analyst estimates of $28.79 million. During the same period in the prior year, the business posted ($0.82) earnings per share. Rhythm Pharmaceuticals’s revenue for the quarter was up 51.3% on a year-over-year basis. As a group, equities analysts predict that Rhythm Pharmaceuticals, Inc. will post -4.44 EPS for the current fiscal year.
Institutional Investors Weigh In On Rhythm Pharmaceuticals
Analyst Ratings Changes
Separately, Needham & Company LLC reiterated a “buy” rating and issued a $55.00 price objective on shares of Rhythm Pharmaceuticals in a report on Wednesday, August 7th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $55.83.
View Our Latest Stock Report on Rhythm Pharmaceuticals
Rhythm Pharmaceuticals Company Profile
Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.
Featured Articles
- Five stocks we like better than Rhythm Pharmaceuticals
- Why is the Ex-Dividend Date Significant to Investors?
- Goldilocks CPI Report Leads Market to Sell Off, Lower Lows Ahead
- Dividend Capture Strategy: What You Need to Know
- GameStop: Earnings Won’t Save It, Dilution Points to Trouble
- The How and Why of Investing in Gold Stocks
- Dividend Aristocrats or Dividend Kings: Which Is Best for You?
Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.